1 online resource (79 pages) : color illustrations, digital file
Contents
Monoclonal antibodies in contemporary cancer therapy / Fatih M. Uckun -- mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatment / Letizia Polito, Rossella Mancuso, Daniele Mercatelli, Massimo Bortolotti & Andrea Bolognesi -- mAbs targeting CTLA-4 and clinical outcomes / Francesco Spagnolo, Virginia Picasso & Paola Queirolo -- mAbs targeting VEGF/VEGFR and clinical outcomes in cancer treatment / Brendan Curley, Michael Newton & Jame Abraham -- mAbs targeting RANKL in bone metastasis treatment / Bérengère Gobin, Marc Baud'Huin, Bertrand Isidor, Dominique Heymann & Marie-Françoise Heymann -- Novel mAb-based therapies for leukemia / Osmond J. D'Cruz & Fatih M. Uckun -- Index
Summary
Monoclonal antibodies (mAbs) have been developed to improve the treatment outcome of cancer patients undergoing therapy according to multimodality regimens without a significant increase of treatment-associated toxicity. This five-chapter book provides examples where mAbs that have become part of the standard of care in cancer patients and cancer types that have responded to mAbs
